Zimbabwe has turned down a major US health deal worth $367m (£272m) over five years due to the United States' request for confidential data.
This rejection came to light following a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesperson has since clarified that the US was requesting biological samples for research and commercial purposes while refused to share the benefits from any future treatments.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more talks to secure a deal acceptable to both sides so the nation's vital HIV programme can continue.
Broader Implications
This rejection follows a similar case in Kenya, where a court halted a related health funding agreement after concerns were filed about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and responsibility.
As per reports, 16 nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment through American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data for a long time, with no corresponding promise of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery without any assurance that the end products would be available to our citizens should a new disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral deals were upending systems previously established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This system is designed to guarantee that when a nation provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be structured in a way that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives relied on foreign aid.
"Where technical issues arise, including those involving information security or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," the group said.
This impasse underscores the complex tensions between accepting much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.